The estimated Net Worth of Lawrence P. Guiheen is at least $2.88 Milion dollars as of 9 September 2024. Mr. Guiheen owns over 9,000 units of Adma Biologics Inc stock worth over $2,755,332 and over the last 11 years he sold ADMA stock worth over $0. In addition, he makes $125,605 as Independent Director at Adma Biologics Inc.
Sign up
Mr. Guiheen ADMA stock SEC Form 4 insiders trading
Lawrence has made over 6 trades of the Adma Biologics Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 9,000 units of ADMA stock worth $97,200 on 9 September 2024.
The largest trade he's ever made was buying 25,000 units of Adma Biologics Inc stock on 17 May 2019 worth over $100,000. On average, Lawrence trades about 4,211 units every 209 days since 2013. As of 9 September 2024 he still owns at least 162,941 units of Adma Biologics Inc stock.
You can see the complete history of Mr. Guiheen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Lawrence Guiheen biography
Lawrence P. Guiheen serves as Independent Director of the Company. Mr. Guiheen became a director of the Company in July 2012 and is currently the Chairman of the Company’s Governance and Nominations Committee and a member of the Company’s Audit Committee. Mr. Guiheen is currently Executive Vice President of Wellstat Management and Chief Executive Officer of Wellmond Therapeutics. Wellmond Therapeutics is a start-up pharmaceutical company located in Rockville, MD. Wellmond is developing and will commercialize drug candidates in oncology supportive care and treatments for diseases and conditions involving mitochondrial and cellular energy disorders or failures. In addition, Mr. Guiheen has over 25 years of experience in the blood and plasma industry. From July 2013 to November 2019, Mr. Guiheen served as Chief Commercial Officer of Kedrion Biopharma, Inc., based in Barga, Italy and Fort Lee, New Jersey. Kedrion markets therapies globally for hemophilia, hemolytic disease of the newborn, immune and neurological disorders. Prior to July 2013, Mr. Guiheen was principal of Guiheen and Associates, a consulting group that specialized in biopharmaceutical, pharmaceutical and medical device commercialization. Before July 2011, Mr. Guiheen was with Baxter Healthcare Corporation for over 30 years. Most recently he held the positions of General Manager Global Hemophilia Franchise (from December 2010 to July 2011), President of Global BioPharmaceuticals for Baxter Healthcare’s BioScience Division (March 2010 to December 2010) and President of BioPharmaceuticals US (January 2004 to March 2010). Mr. Guiheen holds a Bachelor of Arts degree in business administration from Rutgers University. Mr. Guiheen was chosen to serve on the Board of Directors because of his extensive experience in the plasma and pharmaceutical industries.
What is the salary of Lawrence Guiheen?
As the Independent Director of Adma Biologics Inc, the total compensation of Lawrence Guiheen at Adma Biologics Inc is $125,605. There are 9 executives at Adma Biologics Inc getting paid more, with Adam Grossman having the highest compensation of $1,702,020.
How old is Lawrence Guiheen?
Lawrence Guiheen is 69, he's been the Independent Director of Adma Biologics Inc since 2012. There are 5 older and 7 younger executives at Adma Biologics Inc. The oldest executive at Adma Biologics Inc is Dr. James Mond, 74, who is the Exec. VP, Chief Scientific Officer & Chief Medical Officer.
What's Lawrence Guiheen's mailing address?
Lawrence's mailing address filed with the SEC is 465 New Jersey 17 S, Ramsey, NJ 07446, United States.
Insiders trading at Adma Biologics Inc
Over the last 11 years, insiders at Adma Biologics Inc have traded over $43,950,328 worth of Adma Biologics Inc stock and bought 17,510,201 units worth $56,736,742 . The most active insiders traders include Advisors Llcperceptive Life..., Ag Biotest Pharmaceuticals ... a Divestiture Trust Biotest. On average, Adma Biologics Inc executives and independent directors trade stock every 34 days with the average trade being worth of $7,366,858. The most recent stock trade was executed by Lawrence P. Guiheen on 9 September 2024, trading 9,000 units of ADMA stock currently worth $97,200.
What does Adma Biologics Inc do?
adma is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of primary immune deficiency disease (pidd) and certain infectious diseases. adma's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. the target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. adma’s lead product candidate, ri-002, has completed a phase iii clinical trial in patients with pidd and has met the primary endpoint. a bla for ri-002 was accepted by the fda on september 18, 2015. the company has received u.s. patent 9,107,906. for more information, please visit the company's website at www.admabiologics.com.
What does Adma Biologics Inc's logo look like?
Complete history of Mr. Guiheen stock trades at Adma Biologics Inc
Adma Biologics Inc executives and stock owners
Adma Biologics Inc executives and other stock owners filed with the SEC include:
-
Adam Grossman,
President, Chief Executive Officer, Co-Founder, Director -
James Mond,
Executive Vice President, Chief Scientific Officer, Chief Medical Officer -
Adam S. Grossman,
Co-Founder, Pres, CEO & Director -
Brian Lenz,
Chief Financial Officer, Executive Vice President -
Dr. James Mond,
Exec. VP, Chief Scientific Officer & Chief Medical Officer -
Brian Lenz CPA, CPA,
Exec. VP, CFO & GM of ADMA BioCenters -
Jerrold Grossman,
Vice Chairman of the Board, Co-Founder -
Steven Elms,
Independent Chairman of the Board -
Bryant Fong,
Independent Director -
Lawrence Guiheen,
Independent Director -
Dr. Jerrold B. Grossman D.P.S., Ph.D.,
Co-Founder & Vice Chairman -
Dr. Jerrold B. Grossman Ph.D., D.P.S.,
Co-Founder & Vice Chairman -
Martha Demski,
Independent Director -
Cyndi Tolman,
Sr. VP of Plasma Services -
Neal C. Fitzpatrick,
VP of Sales -
Michael Goldstein,
Sr. Director & Gen. Counsel -
Dr. Gene A. Wetzstein BCOP, Pharm.D.,
Exec. Director & Head of Scientific Engagement -
Drew Pantello,
VP of Marketing & Corp. Devel. -
Michael Least,
VP of Sales & Commercial Operations -
Kaitlin Kestenberg,
VP of Compliance, Project Management & Clinical Operations -
Skyler Bloom,
Director of Investor Relations & Corp. Strategy -
Kim Tripodo,
Exec. Director & Head of Human Resource and Admin. Operations -
Eric I Richman,
Director -
Dov A Md Goldstein,
Director -
Ag Biotest Pharmaceuticals ...,
-
Young Kwon,
-
Alison Cecily Finger,
-
Divestiture Trust Biotest,
10% owner -
Steve Elms,
-
Advisors Llcperceptive Life...,
-
Brad L. Tade,
CFO and Treasurer -
Kaitlin M. Kestenberg Messina,
COO and SVP, Compliance